Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;96(17):e6721.
doi: 10.1097/MD.0000000000006721.

Prognostic value of pretreatment 18F-FDG PET-CT for nasopharyngeal carcinoma patients

Affiliations
Review

Prognostic value of pretreatment 18F-FDG PET-CT for nasopharyngeal carcinoma patients

Yecai Huang et al. Medicine (Baltimore). 2017 Apr.

Abstract

Background: Nasopharyngeal carcinoma (NPC) is a special subtype of head and neck cancer (HNC). At present, there are no highly specific prognostic markers to aid in tumor grading and guide patient treatment modalities for NPC. The prognostic value of pretreatment F-fluorodeoxyglucose positron emission tomography-computed tomography (F-PET-CT) in NPC patients is controversial and no consensus exists as to its predictive capability.

Methods: To analyze the predictive efficacy of F-PET-CT imaging in NPC patients, data from MEDLINE, EMBASE, the Cochrane library, CBM, CNKI, and VIP (inception to July 2016) were accessed. Results from prospective and retrospective observational studies that used F-FDG PET to predict disease prognosis in NPC patients were used for analysis. Two authors independently assessed study quality and extracted data. Event-free survival (EFS) was considered the primary endpoint and overall survival rate (OS) was considered the secondary endpoint.

Results: Data from 14 studies and 1134 patients were included in our analysis. The hazard ratios (HRs) of maximum standardized uptake value of primary tumor (SUVmax-T), metabolic tumor volume of primary tumor (MTV-T), and total lesional glycolysis of primary tumor (TLG-T) for EFS were 1.31 (95% confidence interval [CI], 1.11-1.55, P = .001), 2.38 (95% CI 1.53-3.70, P < .001), and 1.65 (95% CI 0.76-3.59, P = .21), respectively. Among studies including TLG-T, those with a fixed SUV of 2.5 had an HR of 3.55 (95% CI, 1.42-8.84, P = .007). The HRs of SUVmax-T and MTV-T for OS were 2.19 (95% CI, 1.47-3.27, P < .001) and 2.69 (95% CI, 1.01-7.17, P = .05), respectively. Among studies including MTV-T, those with a fixed SUV of 2.5 had an HR of 4.07 (95% CI, 2.22-7.46, P < .001). Tests used for assessing predictive value of pretreatment SUVmax, MTV, and TLG of lymph nodes for EFS and OS showed that these parameters did not have significant predictive value (P>.05).

Conclusion: Our results suggested that SUVmax, MTV, and TLG (with a fixed SUV of 2.5) of primary tumors before treatment initiation may be independent prognostic factors for NPC patients; however, SUVmax, MTV, and TLG of metastatic lymph nodes are not.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Study selection process for this study.
Figure 2
Figure 2
Forest plots of HR for events with SUVmax, MTV, and TLG. 1.1. Forest plots of HR for events with SUVmax. 1.2. Forest plots of HR for events with MTV. 1.3. Forest plots of HR for events with TLG. HR = hazard ratio, MTV = metabolic tumor volume, SUVmax = maximum standardized uptake value, TLG = total lesional glycolysis.
Figure 3
Figure 3
Forest plots of HR for death with SUVmax, MTV, and TLG. 2.1. Forest plots of HR for death with SUVmax. 2.2. Forest plots of HR for death with MTV. 2.3. Forest plots of HR for death with TLG. HR = hazard ratio, MTV = metabolic tumor volume, SUVmax = maximum standardized uptake value, TLG = total lesional glycolysis.

Similar articles

Cited by

References

    1. Bruce JP, Yip K, Bratman SV, et al. Nasopharyngeal cancer: molecular landscape. J Clin Oncol 2015;33:3346–55. - PubMed
    1. Feng M, Wang W, Fan Z, et al. Tumor volume is an independent prognostic indicator of local control in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Radiat Oncol 2013;8:208. - PMC - PubMed
    1. Aribas BK, Cetindag F, Ozdogan Z, et al. Nasopharyngeal carcinomas: prognostic factors and treatment features. J Egypt Natl Canc Inst 2008;20:230–6. - PubMed
    1. Liu WS, Wu MF, Tseng HC, et al. The role of pretreatment FDG-PET in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:561–6. - PubMed
    1. Chan SC, Chang JT, Wang HM, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol 2009;45:52–8. - PubMed

MeSH terms

Substances